Collene R Jeter
Overview
Explore the profile of Collene R Jeter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
804
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Awasthi S, Dobrolecki L, Sallas C, Zhang X, Li Y, Khazaei S, et al.
Cell Rep Med
. 2024 Dec;
5(12):101834.
PMID: 39626673
Therapeutic strategies targeting the DNA damage response, such as poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi), have revolutionized cancer treatment in tumors deficient in homologous recombination (HR). However, overcoming innate and...
2.
WRAD core perturbation impairs DNA replication fidelity promoting immunoediting in pancreatic cancer
Citron F, Ho I, Balestrieri C, Liu Z, Yen E, Cecchetto L, et al.
bioRxiv
. 2024 Nov;
PMID: 39484624
It is unclear how cells counteract the potentially harmful effects of uncoordinated DNA replication in the context of oncogenic stress. Here, we identify the WRAD (WDR5/RBBP5/ASH2L/DPY30) core as a modulator...
3.
Mise K, Long J, Galvan D, Ye Z, Fan G, Sharma R, et al.
Nat Commun
. 2024 Apr;
15(1):3022.
PMID: 38589378
No abstract available.
4.
Patel B, Zhou Y, Babcock R, Ma F, Zal M, Kumar D, et al.
Leukemia
. 2024 Mar;
38(5):1143-1155.
PMID: 38467768
Hematopoietic stem and progenitor cells (HSPCs) maintain blood-forming and immune activity, yet intrinsic regulators of HSPCs remain elusive. STAT3 function in HSPCs has been difficult to dissect as Stat3-deficiency in...
5.
Mise K, Long J, Galvan D, Ye Z, Fan G, Sharma R, et al.
Nat Commun
. 2024 Mar;
15(1):1965.
PMID: 38438382
The mitochondrial electron transport chain (ETC) is a highly adaptive process to meet metabolic demands of the cell, and its dysregulation has been associated with diverse clinical pathologies. However, the...
6.
Wible D, Parikh Z, Cho E, Chen M, Jeter C, Mukhopadhyay S, et al.
Cell Death Dis
. 2024 Jan;
15(1):80.
PMID: 38253602
p38 mitogen-activated protein kinases (MAPKs) participate in autophagic signaling; and previous reports suggest that pyridinyl imidazole p38 MAPK inhibitors, including SB203580 and SB202190, induce cell death in some cancer cell-types...
7.
Li Y, Dobrolecki L, Sallas C, Zhang X, Kerr T, Bisht D, et al.
Cell Rep Med
. 2023 Dec;
4(12):101326.
PMID: 38118413
Multiple cancers exhibit aberrant protein arginine methylation by both type I arginine methyltransferases, predominately protein arginine methyltransferase 1 (PRMT1) and to a lesser extent PRMT4, and by type II PRMTs,...
8.
Koutelou E, Wang L, Schibler A, Chao H, Kuang X, Lin K, et al.
Development
. 2019 Feb;
146(4).
PMID: 30718289
USP22, a component of the SAGA complex, is overexpressed in highly aggressive cancers, but the normal functions of this deubiquitinase are not well defined. We determined that loss of USP22...
9.
Liu B, Gong S, Li Q, Chen X, Moore J, Suraneni M, et al.
Oncotarget
. 2017 Sep;
8(32):52746-52760.
PMID: 28881767
This project was undertaken to address a critical cancer biology question: Is overexpression of the pluripotency molecule Nanog sufficient to initiate tumor development in a somatic tissue? Nanog1 is critical...
10.
Jeter C, Liu B, Lu Y, Chao H, Zhang D, Liu X, et al.
Cell Discov
. 2016 Nov;
2:16041.
PMID: 27867534
The pluripotency transcription factor NANOG has been implicated in tumor development, and NANOG-expressing cancer cells manifest stem cell properties that sustain tumor homeostasis, mediate therapy resistance and fuel tumor progression....